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Summary
QUESTIONS UNDER STUDY: As the best management
of subclinical hypothyroidism is controversial, we aimed to
assess variations in treatment strategies depending on dif-
ferent Swiss regions, physician and patient characteristics.
METHODS: We performed a case-based survey among
general practitioners (GPs) in different Swiss regions,
which consisted of eight hypothetical cases presenting a
female patient with subclinical hypothyroidism and non-
specific complaints differing by age, vitality status and
thyroid-stimulating hormone (TSH) concentration.
RESULTS: A total of 262 GPs participated in the survey.
There was considerable variation in the levothyroxine start-
ing dose chosen by GPs, ranging from 25 µg to 100 µg.
Across the Swiss regions, GPs in the Bern region were
significantly more inclined to treat, with a higher prob-
ability of initiating treatment (60%, p = 0.01) and higher
mean starting doses (45 µg, p <0.01) compared with the
French-speaking region (44%, 36 µg); the Zurich region
had intermediate values (52%, 39 µg). We found no asso-
ciation between treatment rate and other physician charac-
teristics. GPs were more reluctant to initiate treatment in
85-year-old than in 70-year-old women (odds ratio [OR]
0.77, 95% confidence interval [CI] 0.63–0.94), and more
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likely to treat women with a TSH of 15 mU/l than those
with a TSH of 6mU/l (OR 8.71, 95% CI 6.21–12.20).
CONCLUSIONS: There are strong variations in treatment
strategies for elderly patients with subclinical hypothyroid-
ism across different Swiss regions, including use of higher
starting doses than the recommended 25 µg in the Swiss
guidelines, which recommend a starting dose of 25 µg.
These variations likely reflect the current uncertainty about
the benefits of treatment, which arise from the current lack
of evidence from adequately powered clinical trials.
Key words: subclinical hypothyroidism; general practice;
survey
Introduction
The prevalence of subclinical hypothyroidism, which is
defined as high thyroid stimulating hormone (TSH) levels
with free thyroxin (fT4) concentrations within the referen-
ce range [1], increases with age and ranges from 3% to
18% in the adult population, with a higher prevalence in
women than men [2, 3]. Subclinical hypothyroidism has
been associated with an increased risk of coronary heart
disease events, heart failure and cardiovascular death [4,
5]. Despite being a common disorder, evidence on the risks
and benefits of screening and treatment is still controver-
sial [6]. A Cochrane review including 350 subclinically
hypothyroid patients from 12 trials with a follow-up time
between 6 and 14 months has concluded that levothyroxine
replacement might improve lipid profiles and left ventricu-
lar function, but that evidence from adequately powered
randomised controlled trials with longer follow-up dura-
tions was needed in order to assess the impact of treatment
on cardiovascular events [7]. Risks of levothyroxine over-
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treatment and consecutive subclinical hyperthyroidism in-
clude an increased risk of atrial fibrillation, heart failure
events and bone loss [5, 8, 9].
A recent international survey that we performed with a sim-
ilar research group has shown large national variations in
strategies for treatment of elderly patients with subclinic-
al hypothyroidism among general practitioners (GPs) from
different countries [10], reflecting the current lack of an in-
ternational consensus concerning the management of these
patients and the wide variations in guideline recommenda-
tions from different medical societies and across countries
[11–14]. In Switzerland, the Swiss Society of Endocrino-
logy and Diabetes has published guidelines on the treat-
ment of subclinical hypothyroidism [13], but no specif-
ic national guidelines for primary care exist. Given this
international variation in the management of elderly pa-
tients with subclinical hypothyroidism, we aimed to assess
whether there were also regional variations in treatment
strategies within one country among Swiss GPs in relation
to different Swiss regions and patient characteristics.
Methods
Study population and survey
We sent an online survey to Swiss GPs, presenting eight
fictional clinical cases involving elderly female patients
with subclinical hypothyroidism (appendix). The survey
was developed using NetQuestionnaire [15] as part of an
international survey to assess variations in treatment
strategies of elderly patients with subclinical hypothyroid-
ism among GPs from different countries [10]. For Switzer-
land, we further aimed to assess the variation in treatment
strategies among Swiss GPs depending on different Swiss
regions. The fictional patients all reported nonspecific fa-
tigue and had a normal body mass index, but varied in age
(70 years vs 85 years), vitality status (vital vs vulnerable)
and TSH levels (6 mIU/l vs 15 mIU/l). In all cases fT4
concentrations were within the reference range. The cases
are described in appendix table 1. After each case descrip-
tion, the GPs were asked the following questions concern-
ing treatment strategy: (1) would you treat this patient with
thyroxine? (2) if yes, what would you recommended as
initiation dose? Furthermore, the GPs were asked to state
whether their treatment strategy would change if the patient
were a man instead of a woman. We also collected the GP’s
gender, the duration of professional experience as a GP and
the percentage of registered elderly persons aged 65 years
or older in their practice. Finally, the GPs were asked to in-
dicate the time since their last diagnosis of subclinical hy-
pothyroidism in a patient aged ≥65 years, and the last time
they had started thyroxine replacement in an elderly patient
with subclinical hypothyroidism.
The survey, which was first developed in English, was
translated and validated by several authors including Ger-
man and French native speakers. German and French ver-
sions of the survey were sent to regional GP institutes in
Geneva, Lausanne, Bern and Zurich, and the institute co-
ordinators circulated an Internet link containing the ques-
tionnaire to all GPs participating in teaching or other activ-
ities related to the institutes within their region between
April and September 2012, with a reminder sent out 2
weeks later. GPs affiliated with the institutes in Geneva
and Lausanne were pooled to represent the French-speak-
ing region of Switzerland; their anonymised answers had
the same site code. Approval from the ethics committees
was exempted since the survey, which treated only fictional
patients, qualified as a peer-audit.
Statistical analysis
Questionnaires with at least one answer to Case 1 provided
by the GP were considered for analysis. Differences in
baseline GP characteristics by region were compared using
chi-square tests. The tendency of GPs to initiate treatment
and levothyroxine starting doses were compared between
GPs from different Swiss regions. GPs were divided into
three different regions based on their affiliation with the
regional GP institutes: Bern region, Zurich region and the
French-speaking region (including the affiliations to the
GP institutes of Lausanne and Geneva). The probability of
the GPs starting treatment was analysed using mixed ef-
fects logistic regression models with GP as a random ef-
fect. The models’ predicted marginal probabilities of ini-
tiating treatment in each region were presented. For com-
parison between the different regions, first an unadjusted
model was used, using the region as a fixed covariate. In a
second step, we adjusted for GP characteristics by adding
the GP’s gender and experience as additional fixed vari-
ables. To test for a trend of increasing experience we in-
cluded this variable as a continuous fixed effect, where a
one unit increase represented 5 years of experience. We fur-
ther analysed the probability of the GPs initiating treatment
in the subgroup of patients with a TSH of 6 mIU/l, includ-
ing only cases 1, 2, 5, and 6. For those who indicated that
they would start treatment, the suggested initial levothyrox-
ine dose was compared between regions using a mixed ef-
fects linear regression and restricted maximum likelihood
(REML) estimation. Nine GPs were excluded from this
analysis because of unrealistic starting doses, such as 1 µg
or 2 µg.
Differences in treatment strategies depending on patient
characteristics (age, vitality status and TSH concentrations)
were calculated with separate odds ratios (ORs) for each
combination of cases that only differed with respect to that
specific characteristic within each Swiss region. Random-
effects models based on the variance model by DerSimoni-
an and Laird [16] were used to calculate a pooled estimate
of the ORs of the different comparisons for each Swiss re-
gion.
Analysis was done using Stata version 13.1 (StataCorp.
2013. Stata Statistical Software: Release 13. College Sta-
tion, TX: StataCorp LP).
Results
Among 1,068 GPs who were contacted, a total of 262 GPs
responded to the survey (Bern region n = 114, Zurich re-
gion n = 81, French-speaking region n = 67), with an over-
all response rate of 25% (appendix table 2). Overall, 235
of all respondents (89.7%) answered to all eight cases,
whereas 27 participants responded to at least one, but not
all cases. The characteristics of the GPs who returned the
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questionnaire are presented in table 1, with slightly more
male GPs participating in Bern. In total, 44% of the re-
spondents indicated that more than 30% of the patients re-
gistered in their practice were aged 65 years or older. With-
in the past year, the vast majority of the GPs (94%) had dia-
Figure 1
Variation in general practitioners’ decision to start treatment
stratified by region. p-values for the difference between the French-
speaking region (reference) and the Zurich or Bern Region,
respectively.
gnosed subclinical hypothyroidism in a patient, and 75%
of the GPs indicated that they had initiated thyroxine treat-
ment in an elderly patient with subclinical hypothyroidism.
Figure 2
Starting dose of levothyroxine chosen by general practitioners
according to region.
Table 1: Characteristics of the general practitioners who participated in the survey.
Total Bern region Zurich region French-speaking
region
Characteristic
n = 262 n = 114 n = 81 n = 67
p-value
Men 213 (81%) 100 (88%) 64 (79%) 49 (73%) 0.04
More than 15 years of clinical experience 168 (64%) 73 (64%) 47 (58%) 48 (72%) 0.23
>30% patients in the practice aged ≥65 years 114 (44%) 56 (49%) 29 (36%) 29 (43%) 0.18
Diagnosis of subclinical hypothyroidism in a patient <1 year ago 246 (94%) 110 (96%) 75 (93%) 61 (91%) 0.28
Started thyroxine treatment in a patient <1 year ago 196 (75%) 88 (77%) 61 (75%) 47 (70%) 0.57
Note: Data are presented as n (%); p- values were obtained by chi-squared tests.
Adapted from [10].
Table 2: Mixed effects logistic regression for the probability of providing treatment.
Variable GPs (n) Treatment rate OR (95% CI) p-value
Unadjusted model
French-speaking region 67 44% Reference
Zurich region 81 52% 1.40 (0.82–2.39) 0.22
Bern region 114 60% 1.92 (1.16–3.16) 0.01
Adjusted model*
French-speaking region 45% Reference
Zurich region 51% 1.30 (0.76–2.22) 0.34
Bern region 59% 1.80 (1.08–2.98) 0.02
GP gender (female) 49 0.84 (0.48–1.44) 0.519
Years of clinical practice <5 years 13 Reference 0.216
5–10 years 35 0.82 (0.29–2.30)
11–15 years 46 1.31 (0.48–3.56)
16–20 years 47 0.90 (0.33–2.47)
21–25 years 42 1.37 (0.49–3.82)
>25 years 79 0.69 (0.26–1.82)
Trend per 5 years’ experience 0.94 (0.82–1.07) 0.354
Including only patients with a TSH of 6 mU/l
Unadjusted model
French-speaking region 67 7% Reference
Zurich region 81 7% 1.01 (0.33–3.13) 0.98
Bern region 114 16% 2.36 (0.83–6.74) 0.11
Adjusted model*
French-speaking region 8% Reference
Zurich region 8% 1.03 (0.32–3.24) 0.97
Bern region 17% 2.49 (0.85–7.31) 0.10
GPs’ decisions to treat or not to treat were the binary outcomes. GP ID was included as a random effect to control for within GP correlation.
CI = confidence interval; GP = general practitioner; OR = odds ratio; *Adjusted for GP’s gender and year’s of experience
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The GPs’ inclination to initiate treatment differed signi-
ficantly between regions (p = 0.036), with GPs from the
Bern region being more inclined to initiate thyroxine treat-
ment with a predicted treatment rate of 60% compared with
GPs from the Zurich region (52%) or the French-speak-
ing region (44%, fig. 1). This resulted in a significantly
higher odds of thyroxine use in the Bern region (p = 0.01)
compared with the French-speaking region, also after ad-
justment for GP’s gender and years of clinical experience
(table 2). The probability of a female GP initiating thyrox-
ine treatment did not differ from that of male doctors. The
number of years of clinical experience was not signific-
antly associated with treatment rate. In the subgroup of
patients with a TSH of 6 mIU/l, the probability of start-
ing treatment was increased in GPs from the Bern region
with a treatment rate of 16% compared with those from the
Zurich and French-speaking regions (treatment rates 7%),
although the difference was not statistically significant (p =
0.10–0.11).
Thyroxine starting doses varied from 25 µg to 100 µg and
differed significantly across regions (p <0.01, table 3). GPs
in the Bern region implemented the highest starting dose
(predicted mean starting dose 45 µg, p <0.01) compared
with the French-speaking region (36 µg), whereas the mean
starting dose implemented by GPs in the Zurich region was
39 µg. The starting doses chosen by the GPs according to
the different regions pooled for all cases are shown in fig-
ure 2, and the distribution of the starting doses for each case
is illustrated in appendix figure 2.
Swiss GPs were more reluctant to initiate treatment in
85-year-old than in 70-year-old women (pooled OR 0.77,
95% confidence interval [CI] 0.63–0.94, Appendix fig. 2),
and women with a TSH of 15 mU/l were treated more often
than those with a TSH of 6 mU/l (pooled OR 8.71, 95% CI
6.21–12.20). Vitality status of the patient did not influen-
ce the treatment strategy. These results did not significantly
differ across regions.
The majority of the GPs in all regions stated that they
would not change their treatment strategy if the patient
were male rather than female (percentage ‘no change’:
Zurich region 98.6%, Bern region 95.3%, French-speaking
region 94.7%, p = 0.46; appendix table 3).
Discussion
Treatment strategies of elderly patients with subclinical hy-
pothyroidism vary considerably throughout the different
Swiss regions in terms of initiation of thyroxine treatment
and starting dose, with GPs in the Bern region treating
more often and with higher doses, whereas GPs in the
Zurich and French-speaking regions were less inclined to
treat and implemented lower starting doses. Starting doses
varied from 25 to 100 µg, whereas the Swiss Society for
Endocrinology and Diabetes recommends a thyroxine start-
ing dose of 25 µg in patients older than 50 years [13], like
those in our survey. GPs were more inclined to start treat-
ment in patients with higher TSH levels and younger age.
Few previous studies have assessed treatment strategies for
subclinical hypothyroidism, and none has highlighted re-
gional differences within a single country. Our previous
international survey on the treatment of subclinical hypo-
thyroidism in elderly patients found large variations in GP
treatment strategies across different countries, with treat-
ment rates varying between 34% in the Netherlands and
73% in Germany [10]. In line with our results, the inter-
national survey showed that younger age and higher TSH
levels were positively associated with the decision of the
GPs to start treatment [10]. In a case-based survey in the
United States, the management of patients with overt and
subclinical hypothyroidism differed significantly between
primary care physicians and members of the American
Thyroid Association [17]. Treatment decisions in individu-
als with subclinical hypothyroidism varied according to
different clinical factors among international members of
different American endocrine societies as shown in a recent
survey [18]. Sixty-two percent of the 802 respondents in-
dicated that they would initiate treatment in the presence
of positive thyroid peroxidase antibodies, 47% would start
treatment in a patient with goitre and 26% in those with
known cardiovascular disease. These results probably re-
flect the inconsistent recommendations from different na-
tional guidelines and the lack of an international consensus
as to whether or not subclinical hypothyroidism should be
treated [1, 7, 11]. The Swiss Society for Endocrinology
and Diabetes guidelines [13] recommend basing the de-
cision to initiate treatment on a risk assessment, taking into
consideration a TSH value >10 mIU/l, prevalent goitre,
thyroid-peroxidase antibodies, cardiovascular risk factors
or coronary heart disease, clinical symptoms, ovulary dys-
Table 3: Initial thyroxine dose suggested by doctors who would initiate treatment.
Variable GPs (n) Predicted starting
dose in µg (95% CI)
Coef. (95% CI) p-value
Unadjusted model
French-speaking region 64 36.1 (32.2‒40.0) Reference
Zurich region 77 39.4 (36.1‒42.8) 3.3 (–1.8 ‒ 8.5) 0.20
Bern region 112 44.6 (41.2‒48.1) 8.5 (3.3‒13.8) <0.01
Adjusted for gender and years of experience
French-speaking region 36.0 (31.6‒40.5) Reference
Zurich region 39.3 (35.4‒43.2) 3.3 (–2.6 ‒ 9.2) 0.28
Bern region 44.7 (41.5‒47.8) 8.7 (3.2‒14.1) <0.01
Analysis by mixed effects linear regression including GP ID as a random effect. Predicted dose are the predicted marginal means, adjusted or unadjusted, for each site.
The p-value for a general difference between the three regions was <0.01 for the unadjusted and <0.01 for the adjusted model. Coefficients represent the difference from
the reference level.
CI = confidence interval; Coef. = coefficient; GP = general practitioner
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function, and pregnancy. In the presence of any of these
risk factors, the initiation of thyroxine replacement is re-
commended with a starting dose of 25 µg in patients older
than 50 years or those with known coronary heart disease;
in all other patients, thyroxine treatment can be started at a
dose of 50 to 75 µg [13]. In our study, the GPs implemen-
ted higher starting doses than recommended for elderly pa-
tients in the Swiss guidelines. The European Thyroid Asso-
ciation published similar recommendations with thyroxine
starting doses of 25–50 µg in elderly persons with subclin-
ical hypothyroidism [19], and the guidelines of the Americ-
an Association of Clinical Endocrinologists and the Amer-
ican Thyroid Association recommend a thyroxine starting
dose of 50 µg in individuals older than 50–60 years, which
should be reduced to 12.5–25 µg in those with concomitant
coronary heart disease [20].
Our study has some limitations. First, the overall response
rate was 25%, limiting the generalisability of our results.
However, the response rate in our survey was similar to
the response rate seen in a previous survey on subclinical
hypothyroidism among American primary care physicians
[17], and the problem of achieving high response rates in
GP surveys has been recognised [21]. Participation rates
differed across regions, possibly introducing nonresponse
bias, although this risk seems to be lower in physician sur-
veys than in surveys performed among the general pop-
ulation [22]. We did not have a clear explanation for the
different participation rates across regions, but potential ex-
planations might be the number of ongoing studies taking
place at a similar time or differences in the degree of in-
volvement of GPs with their regional institutes. As the sur-
vey presented only hypothetical cases with a short case de-
scription, comparability to real-life cases might be limited.
Another limitation is the restricted choice of possible an-
swers, not allowing the option of watchful waiting with
monitoring of TSH levels to be chosen [6, 23]. Further-
more, we were not able to adjust for other possible con-
founding factors such as the willingness of the patient to
receive treatment or the GP’s affiliation to primary care
networks.
Our results likely reflect the current uncertainties regarding
the benefits of thyroxine treatment in elderly patients with
subclinical hypothyroidism, not only across countries but
also across different regions of the same country, where
GPs work with the same national guidelines [13]. Possible
explanations are recommendations by local experts within
training rounds or different teaching about managing sub-
clinical hypothyroidism. Because of the lack of specific
primary care guidelines in Switzerland, local GP networks
and associations have created their own “unofficial”
guidelines [24], which are often discussed in quality
circles, with a known effect on prescribing patterns [25].
In contrast to the national guidelines, these standards are
created by physicians associated with these specific net-
works. It has been shown that treatment strategies from
Swiss GPs working in networks differed from those of GPs
in usual primary care [26]. Therefore, the proportion of
GPs associated with specific networks could explain some
regional differences, but these data were not collected in
the present survey. Furthermore, GPs might follow differ-
ent guidelines, such as those from the American Thyroid
Association [20] and the European Thyroid Association
[19], that recommend higher starting doses in nonelderly
patients than the Swiss Society for Endocrinology and Dia-
betes guidelines and may have higher levels of dissemina-
tion among GPs in some regions. Another possible explan-
ation for the regional differences despite uniform national
guidelines might be a limited adherence to evidence-based
treatment guidelines in primary care [27]. Data from clin-
ical trials assessing the benefits and risks of treatment of
subclinical hypothyroidism are needed in order to obtain
evidence-based recommendations for guideline develop-
ment and inform clinical decisions. The TRUST trial
(Thyroid hormone Replacement for Untreated older adults
with Subclinical hypothyroidism: a randomized placebo-
controlled Trial) is a large multinational multicentre
placebo-controlled randomised clinical trial currently on-
going in four European countries including Switzerland.
This trial aims to investigate the benefits and risks of
thyroxine replacement among elderly persons with subclin-
ical hypothyroidism [28]. An additional substudy in the
oldest old is currently underway in the Netherlands as the
IEMO 80-Plus Thyroid Trial [23, 29] with recruitment of
individuals aged 80 years and older.
In conclusion, our findings show that there are important
variations in treatment strategies of elderly patients with
subclinical hypothyroidism throughout the different Swiss
regions, including application of higher starting doses than
recommended in the Swiss guidelines. These variations re-
flect the current uncertainty regarding the benefits of treat-
ment and emphasise the importance of ongoing clinical
trials for obtaining strong evidence-based treatment recom-
mendations.
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Appendix
The survey (English version)
This survey was previously published in [10].
Survey
1. What is your gender?
O Male
O Female
2. How many years have you been practicing as a GP?
O <5
O 5-10
O 11-15
O 16-20
O 21–25
O >25
3. What percentage of patients in your practice is 65 years or above?
O <10
O 10–20
O 20–30
O >30
4. When did you last diagnose a patient over 65 with subclinical hypothyroidism in your practice?
O Less than 1 week ago
O Less than 1 month ago
O Less than 1 year ago
O Less than 3 years ago
O More than 3 years ago
5. When did you last start thyroxin treatment in a patient over 65 with subclinical hypothyroidism?
O Less than 1 week ago
O Less than 1 month ago
O Less than 1 year ago
O Less than 3 years ago
O More than 3 years ago
O Never
In each case we discuss an older woman of average height and weight, presenting with aspecifc complaints of fatigue. You found sufficient
reason in her complaints to perform a blood test. The test showed subclinical hypothyroidism.
6. Case 1.
Female, 70 years old, vital
Elevated TSH: 6 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 6c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
c) Explanation (optional)
7. Case 2.
Female, 70 years old, vulnerable.
Elevated TSH: 6 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 7c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
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c) Explanation (optional)
8. Case 3.
Female, 70 years old, vital.
Elevated TSH: 15 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 8c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
c) Explanation (optional)
9. Case 4.
Female, 70 years old, vulnerable.
Elevated TSH: 15 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 9c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
c) Explanation (optional)
10. Case 5.
Female, 85 years old, vital
Elevated TSH: 6 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 10c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
c) Explanation (optional)
11. Case 6.
Female, 85 years old, vulnerable
Elevated TSH: 6 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 11c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
c) Explanation (optional)
12. Case 7.
Female, 85 years old, vital.
Elevated TSH: 15 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 12c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
c) Explanation (optional)
13. Case 8.
Female, 85 years old, vulnerable.
Elevated TSH: 15 mU/L (reference range 0.5–4.4 mU/L).
Free T4 is within the reference range (13–25 pMol/L).
a) Would you start thyroxin treatment?
O Yes
O No → go to question 13c
b) To start treatment, how much thyroxin (mcg) would you prescribe?
c) Explanation (optional)
Original article Swiss Med Wkly. 2015;145:w14156
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 13
14a) Would you act any differently if the patient was an older male of average weight and normal BMI instead of a woman?
O Yes, go to 14b
O No, go to 15
b) Explanation
15. Would you like to be informed about the results of this study?
O Yes, à email address
O No
Comments:
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Appendix
Appendix figure 1
Factors associated with general practitioners’ decision to start treatment according to region
TSH = thyroid stimulating hormone.
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Appendix figure 2
Starting dose of levothyroxine chosen by general practitioners for each case according to region.
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Appendix table 1: The eight clinical cases.
Case Gender Age (years) TSH (mIU/l) Vitality status
1 Woman 70 6 Vital
2 Woman 70 6 Vulnerable
3 Woman 70 15 Vital
4 Woman 70 15 Vulnerable
5 Woman 85 6 Vital
6 Woman 85 6 Vulnerable
7 Woman 85 15 Vital
8 Woman 85 15 Vulnerable
All cases presented in the survey involved an older female patient with a normal free thyroxine level, a normal body mass index and nonspecific symptoms resulting in
fatigue.
TSH = thyroid-stimulating hormone. Adapted from [10]
Appendix table 2: Participating Swiss regional general practitioner (GP) institutes.
Region Regional GP institute Number of GPs invited to
participate
Number of GPs who
participated
Response
Rate
Zurich region Institute of General Practice and Health Services
Research, University of Zurich
478 81 17%
Bern region Bern Institute of General Practice, University of Bern 260 114 44%
Institute of General Medicine, University of Lausanne*French-speaking region
Department of Community Medicine and Primary Care,
Geneva University Hospitals*
330 67 20%
Total 1,068 262 25%
* 18 GPs could not be allocated to Geneva or Lausanne owing to insufficient data (data collected together), and were excluded from this subgroup analysis.
Appendix table 3: Would treatment strategy change for a male patient?
Site Total Yes No p-p-value
Zurich region 72 1 (1.4%) 71 (98.6%)
Bern region 106 5 (4.7%) 101 (95.3%)
French-speaking region 57 3 (5.3%) 54 (94.7%)
0.46
Data are presented as n (%).The p-value was derived using Fisher's exact test. Data are missing for 27 general practitioners (9 from Bern region, 8 from Zurich region, 10
from French-speaking region).
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Figures (large format)
Figure 1
Variation in general practitioners’ decision to start treatment stratified by region. p-values for the difference between the French-speaking region
(reference) and the Zurich or Bern Region, respectively.
Figure 2
Starting dose of levothyroxine chosen by general practitioners according to region.
Original article Swiss Med Wkly. 2015;145:w14156
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 13 of 13
